title: Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases.
abstract: We investigated red blood cell (RBC) PUFA profiles, and the predictive value of RBC EPA content for tumour EPA exposure and clinical outcomes, in the EMT study, a randomised trial of EPA in patients awaiting colorectal cancer (CRC) liver metastasis surgery (Cockbain et al., 2014) [8]. There was a significant increase in RBC EPA in the EPA group (n=43; median intervention 30 days; mean absolute 1.26[±0.14]% increase; P<0.001), but not in the placebo arm (n=45). EPA incorporation varied widely in EPA users and was not explained by treatment duration or compliance. There was little evidence of 'contamination' in the placebo group. The EPA level predicted tumour EPA content (r=0.36; P=0.03). Participants with post-treatment EPA≥1.22% (n=49) had improved OS compared with EPA <1.22% (n=29; HR 0.42[95%CI 0.16-0.95]). RBC EPA content should be evaluated as a biomarker of tumour exposure and clinical outcomes in future EPA trials in CRC patients.
authors.affiliation: Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, St James's University Hospital, Leeds LS9 7TF, United Kingdom; Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds LS9 7TF, United Kingdom.
authors.forename: Henry
authors.initials: H
authors.lastname: Watson
authors.affiliation: Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, St James's University Hospital, Leeds LS9 7TF, United Kingdom; Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds LS9 7TF, United Kingdom.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Cockbain
authors.affiliation: Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, United Kingdom.
authors.forename: Jade
authors.initials: J
authors.lastname: Spencer
authors.affiliation: Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, United Kingdom.
authors.forename: Amanda
authors.initials: A
authors.lastname: Race
authors.affiliation: Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, St James's University Hospital, Leeds LS9 7TF, United Kingdom.
authors.forename: Milene
authors.initials: M
authors.lastname: Volpato
authors.affiliation: Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, United Kingdom.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Loadman
authors.affiliation: Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds LS9 7TF, United Kingdom.
authors.forename: Giles J
authors.initials: GJ
authors.lastname: Toogood
authors.affiliation: Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, St James's University Hospital, Leeds LS9 7TF, United Kingdom. Electronic address: M.A.Hull@leeds.ac.uk.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Hull
mesh_terms: D015179:Colorectal Neoplasms / Q000097:blood* / Q000378:metabolism; D018572:Disease-Free Survival; D004309:Double Bind Interaction; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage*; D015525:Fatty Acids, Omega-3 / Q000097:blood*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000378:metabolism / Q000556:secondary; D008297:Male; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D015525:Fatty Acids, Omega-3; D015118:Eicosapentaenoic Acid
keywords: Colorectal cancer; Eicosapentaenoic acid; Omega-3 polyunsaturated fatty acid